{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T20:49:09Z","timestamp":1778964549670,"version":"3.51.4"},"reference-count":68,"publisher":"Elsevier BV","issue":"36","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,7,7]],"date-time":"2015-07-07T00:00:00Z","timestamp":1436227200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.vaccine.2015.06.011","type":"journal-article","created":{"date-parts":[[2015,7,16]],"date-time":"2015-07-16T02:04:49Z","timestamp":1437012289000},"page":"4437-4445","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Vaccination with a multicomponent meningococcal B vaccine in prevention of disease in adolescents and young adults"],"prefix":"10.1016","volume":"33","author":[{"given":"Terry","family":"Nolan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel","family":"O\u2019Ryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Wassil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9283-7689","authenticated-orcid":false,"given":"V\u00e9ronique","family":"Abitbol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Dull","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2015.06.011_bib0345","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1478-7954-11-17","article-title":"Global epidemiology of invasive meningococcal disease","volume":"11","author":"Jafri","year":"2013","journal-title":"Popul Health Metics"},{"key":"10.1016\/j.vaccine.2015.06.011_bib0350","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-61779-346-2_1","article-title":"Neisseria meningitidis: biology, microbiology, and epidemiology","volume":"799","author":"Rouphael","year":"2012","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.vaccine.2015.06.011_bib0355","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1056\/NEJM200105033441807","article-title":"Meningococcal disease","volume":"344","author":"Rosenstein","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2015.06.011_bib0360","series-title":"Surveillance of invasive bacterial diseases in Europe 2008\/2009","author":"European Centre for Disease Prevention and Control","year":"2011"},{"key":"10.1016\/j.vaccine.2015.06.011_bib0365","doi-asserted-by":"crossref","first-page":"B51","DOI":"10.1016\/j.vaccine.2009.04.063","article-title":"Global epidemiology of meningococcal disease","volume":"27S","author":"Harrison","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.06.011_bib0370","series-title":"Report prepared for the Ministry of Health by the Institute of Environmental Science and Research (ESR)","article-title":"The epidemiology of meningococcal disease in New Zealand in 2003","author":"Martin","year":"2004"},{"key":"10.1016\/j.vaccine.2015.06.011_bib0375","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1046\/j.1440-1754.2001.00722.x","article-title":"A 10-year serogroup B meningococcal disease epidemic in New Zealand: descriptive epidemiology, 1991\u20132000","volume":"37","author":"Baker","year":"2001","journal-title":"J Paediatr Child Health"},{"key":"10.1016\/j.vaccine.2015.06.011_bib0380","series-title":"Guidelines for the early clinical and public health management of meningococcal disease in Australia. Revised Edition 2007. Communicable Diseases Network Australia: Commonwealth Department of Health and Ageing","year":"2007"},{"issue":"47","key":"10.1016\/j.vaccine.2015.06.011_bib0385","first-page":"521","article-title":"Meningococcal vaccines: WHO position paper, November 2011","volume":"86","author":"World Health Organization (WHO)","year":"2011","journal-title":"Wkly Epidemiol Rec"},{"issue":"12","key":"10.1016\/j.vaccine.2015.06.011_bib0390","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/S1473-3099(10)70251-6","article-title":"Meningococcal carriage by age: a systematic review and meta-analysis","volume":"10","author":"Christensen","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2015.06.011_bib0395","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1007\/s10096-013-1897-6","article-title":"Meningococcal carriage during a clonal meningococcal B outbreak in France","volume":"32","author":"Delbos","year":"2013","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2015.06.011_bib0400","doi-asserted-by":"crossref","first-page":"950","DOI":"10.3201\/eid1206.051297","article-title":"Social behavior and meningococcal carriage in British teenagers","volume":"12","author":"MacLennan","year":"2006","journal-title":"Emerg Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2015.06.011_bib0405","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.3201\/eid1809.120257","article-title":"Trends in meningococcal disease in the United States military, 1971\u20132010","volume":"18","author":"Broderick","year":"2012","journal-title":"Emerging Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2015.06.011_bib0410","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1586\/14760584.2013.814879","article-title":"The current situation of meningococcal disease in Latin America and recommendations for a new case definition from the Global Meningococcal Initiative","volume":"12","author":"S\u00e1fadi","year":"2013","journal-title":"Expert Rev Vaccines"},{"issue":"6","key":"10.1016\/j.vaccine.2015.06.011_bib0415","doi-asserted-by":"crossref","first-page":"990","DOI":"10.3201\/eid1406.071357","article-title":"Serogroup Y meningococcal disease, Columbia","volume":"15","author":"In\u00e9s Agudelo","year":"2008","journal-title":"Emerg Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2015.06.011_bib0420","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3855\/jidc.1518","article-title":"Epidemiology of meningococcal disease in the Panamanian pediatric population, 1998\u20132008","volume":"5","author":"Nieto-Guevara","year":"2011","journal-title":"J Infect Dev Ctries"},{"issue":"2","key":"10.1016\/j.vaccine.2015.06.011_bib0425","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jinf.2009.06.001","article-title":"Molecular characterization of invasive serogroup Y Neisseria meningitidis strains isolated in the Latin America region","volume":"59","author":"Abad","year":"2009","journal-title":"J Infect"},{"issue":"11","key":"10.1016\/j.vaccine.2015.06.011_bib0430","doi-asserted-by":"crossref","first-page":"e50659","DOI":"10.1371\/journal.pone.0050659","article-title":"The changing epidemiology of meningococcal disease in Qu\u00e9bec, Canada, 1991\u20132011: potential implications of emergence of new strains","volume":"7","author":"Gilca","year":"2012","journal-title":"PLoS ONE"},{"issue":"16","key":"10.1016\/j.vaccine.2015.06.011_bib0435","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1001\/jama.281.16.1493","article-title":"Epidemic serogroup B meningococcal disease in Oregon: the evolving epidemiology of the ET-5 strain","volume":"281","author":"Diermayer","year":"1999","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.vaccine.2015.06.011_bib0440","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1099\/0022-1317-51-9-717","article-title":"Impact of meningococcal C conjugate vaccine in the UK","volume":"51","author":"Balmer","year":"2002","journal-title":"J Med Microbiol"},{"issue":"2","key":"10.1016\/j.vaccine.2015.06.011_bib0445","doi-asserted-by":"crossref","first-page":"B20","DOI":"10.1016\/j.vaccine.2009.04.067","article-title":"Meningococcal C conjugate vaccine: the experience in England and Wales","volume":"27","author":"Campbell","year":"2009","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2015.06.011_bib0450","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/01.inf.0000195594.41449.c6","article-title":"Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands","volume":"25","author":"de Greeff","year":"2006","journal-title":"Pediatric Infect Dis J"},{"issue":"2","key":"10.1016\/j.vaccine.2015.06.011_bib0455","first-page":"208","article-title":"Vaccine against group B Neiserria meningitidis: protection trial and mass vaccination results in Cuba","volume":"14","author":"Sierra","year":"1991","journal-title":"NIPH Ann"},{"issue":"4","key":"10.1016\/j.vaccine.2015.06.011_bib0460","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1590\/S0074-02761999000400002","article-title":"Epidemiological impact of antimeningococcal B vaccination in Cuba","volume":"94","author":"P\u00e9rez Rodr\u00edguez","year":"1999","journal-title":"Mem Inst Oswaldo Cruz, Rio de Janeiro"},{"key":"10.1016\/j.vaccine.2015.06.011_bib0465","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1016\/j.vaccine.2005.01.063","article-title":"MeNZBTM: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strain","volume":"23","author":"Oster","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.06.011_bib0470","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/aje\/kwm147","article-title":"A prospective study of the effectiveness of the New Zealand meningococcal B vaccine","volume":"166","author":"Kelly","year":"2007","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2015.06.011_bib0475","first-page":"671","article-title":"National and state vaccination coverage among adolescents aged 13\u201317 years\u2014United States, 2011","volume":"61","author":"Centers for Disease Control and Prevention","year":"2012","journal-title":"MMWR"},{"issue":"S2","key":"10.1016\/j.vaccine.2015.06.011_bib0480","doi-asserted-by":"crossref","first-page":"S389","DOI":"10.2105\/AJPH.2008.151332","article-title":"Compliance with multiple-dose vaccine schedules among older children, adolescents, and adults: results from a vaccine safety datalink study","volume":"99","author":"Nelson","year":"2009","journal-title":"Am J Public Health"},{"issue":"3","key":"10.1016\/j.vaccine.2015.06.011_bib0485","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.vaccine.2011.11.042","article-title":"Compliance with recommended dosing intervals for HPV vaccination among females, 13\u201317 years, National Immunization Survey-Teen, 2008\u20132009","volume":"30","author":"Dorella","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.06.011_bib0490","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/0140-6736(91)91961-S","article-title":"Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway","volume":"338","author":"Bjune","year":"1991","journal-title":"Lancet"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2015.06.011_bib0495","doi-asserted-by":"crossref","first-page":"B3","DOI":"10.1016\/j.vaccine.2009.04.071","article-title":"Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis","volume":"27","author":"Holst","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.06.011_bib0500","first-page":"48","article-title":"Delivering a safe and effective strain-specific vaccine to control an epidemic of group B meningococcal disease","volume":"122","author":"O\u2019Hallahan","year":"2009","journal-title":"N Z Med J"},{"key":"10.1016\/j.vaccine.2015.06.011_bib0505","doi-asserted-by":"crossref","first-page":"10834","DOI":"10.1073\/pnas.0603940103","article-title":"A universal vaccine for serogroup B meningococcus","volume":"103","author":"Giuliani","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"45","key":"10.1016\/j.vaccine.2015.06.011_bib0510","doi-asserted-by":"crossref","first-page":"19490","DOI":"10.1073\/pnas.1013758107","article-title":"Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines","volume":"107","author":"Donnelly","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2015.06.011_bib0515","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.1016\/j.vaccine.2011.04.092","article-title":"Prevalence and genetic diversity of candidate vaccine antigens against invasive Neisseria meningitidis isolates in the United States","volume":"29","author":"Wang","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.06.011_bib0520","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.vaccine.2012.12.022","article-title":"Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa?","volume":"31","author":"Hong","year":"2013","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2015.06.011_bib0525","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1128\/CVI.00304-10","volume":"18","author":"Kimura","year":"2011","journal-title":"Clin vaccine Immunol"},{"key":"10.1016\/j.vaccine.2015.06.011_bib0530","doi-asserted-by":"crossref","first-page":"646","DOI":"10.4161\/hv.7.6.15482","article-title":"The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans","volume":"7","author":"Toneatto","year":"2011","journal-title":"Hum Vaccin"},{"issue":"9816","key":"10.1016\/j.vaccine.2015.06.011_bib0535","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/S0140-6736(11)61713-3","article-title":"Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b\/3 randomised, observer-blind, placebo-controlled study","volume":"379","author":"Santolaya","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2015.06.011_bib0540","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1016\/S0140-6736(14)60842-4","article-title":"Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial","volume":"384","author":"Read","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2015.06.011_bib0545","series-title":"Protocol Immunization Qu\u00e9bec (PIQ) Edition 6. Publication No. 13-283-06E","year":"2014"},{"key":"10.1016\/j.vaccine.2015.06.011_bib0550","series-title":"Institut national de sant\u00e9 publique du Qu\u00e9bec (INSPQ). Rapport interimaire de surveillance de la securite de la premiere dose du vaccin contre le meningocoque de serogroupe B au Saguenay\u2212Lac-Saint-Jean","year":"2015"},{"key":"10.1016\/j.vaccine.2015.06.011_bib0555","series-title":"Kinetics of the immune response to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents. Submission under review in Vaccine as of December","author":"Perrett","year":"2014"},{"key":"10.1016\/j.vaccine.2015.06.011_bib0560","series-title":"Presented at: 18th International Pathogenic Neisseria Conference (IPNC) Meeting","article-title":"Safety and immunogenicity of a four component meningococcal group B vaccine (4CMenB) and a quadrivalent meningococcal group A, C, W135 and Y conjugate vaccine (Menveo) in UK laboratory workers with potential occupational exposure to meningococci","author":"Findlow","year":"2012"},{"key":"10.1016\/j.vaccine.2015.06.011_bib0565","series-title":"Presented at: ACIP February 2014 Meeting","article-title":"Outbreak of serogroup B meningococcal disease on university campuses \u2013 2013. Meningitis and Vaccine Preventable Diseases Branch, CDC","author":"Patel","year":"2014"},{"issue":"5","key":"10.1016\/j.vaccine.2015.06.011_bib0570","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1586\/erv.11.32","article-title":"A combination recombinant protein and outer membrane vesicle vaccine against serogroup B meningococcal disease","volume":"10","author":"Su","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2015.06.011_bib0575","series-title":"Presented at: MRF 2013","article-title":"Bactericidal antibody levels following quadrivalent conjugate (MenACWY-CRM) or serogroup B (4CMenB) meningococcal vaccines in a phase 3 study to evaluate the effect of vaccination on pharyngeal carriage of N. Meningitidis in young adults","author":"Dull","year":"2013"},{"issue":"11","key":"10.1016\/j.vaccine.2015.06.011_bib0580","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.4161\/hv.25505","article-title":"Persistence of antibodies in adolescents 18-24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine","volume":"9","author":"Santolaya","year":"2013","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.vaccine.2015.06.011_bib0585","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1473-3099(13)70006-9","article-title":"Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment","volume":"13","author":"Vogel","year":"2013","journal-title":"Lancet Infect Dis."},{"key":"10.1016\/j.vaccine.2015.06.011_bib0590","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1126\/science.287.5459.1816","article-title":"Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing","volume":"287","author":"Pizza","year":"2000","journal-title":"Science"},{"issue":"43","key":"10.1016\/j.vaccine.2015.06.011_bib0595","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1016\/j.vaccine.2013.08.006","article-title":"Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage","volume":"31","author":"Frosi","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.06.011_bib0600","series-title":"Poster presented at: 18th International Pathogenic Neisseria Conference (IPNC) Meeting","article-title":"MATS based coverage prediction for the 4CMenB vaccine on Neisseria meningitides B (MenB) Brazilian invasive strains","author":"Lemos","year":"2012"},{"key":"10.1016\/j.vaccine.2015.06.011_bib0605","series-title":"XVIIIth International Pathogenic Neisseria conference","article-title":"Use of the Meningococcal Antigen Typing System (MATS) to assess the Australian meningococcal strain coverage with a multicomponent serogroup B vaccine","author":"Nissen","year":"2012"},{"issue":"2014","key":"10.1016\/j.vaccine.2015.06.011_bib0610","first-page":"124","article-title":"Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CmenB)","volume":"32","author":"Bettinger","year":"2014","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2015.06.011_bib0615","first-page":"103","article-title":"Predicted strain coverage of a new protein-based meningococcal vaccine in the Czech Republic","volume":"63","author":"K\u0159\u00ed\u017eov\u00e1","year":"2014","journal-title":"Epidemiol Mikrobiol Imunol"},{"key":"10.1016\/j.vaccine.2015.06.011_bib0620","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/1471-2180-14-111","article-title":"Diversity of Greek meningococcal serogroup B isolates and estimated coverage of the 4CMenB meningococcal vaccine","volume":"14","author":"Tzanakaki","year":"2014","journal-title":"BMC Microbiol"},{"key":"10.1016\/j.vaccine.2015.06.011_bib0625","series-title":"Presented at: 18th International Pathogenic Neisseria Conference (IPNC) Meeting","article-title":"Meningococcal antigen typing system (MATS) based coverage prediction for the 4CMenB vaccine in the United States","author":"Kim","year":"2012"},{"key":"10.1016\/j.vaccine.2015.06.011_bib0630","series-title":"Presented at: Current Issues in Immunization NetConferences","article-title":"Serogroup B meningococcal outbreaks and control. Meningitis and Vaccine Preventable Diseases Branch, CDC","author":"Cohn","year":"2014"},{"key":"10.1016\/j.vaccine.2015.06.011_bib0635","unstructured":"Centers for Disease Control and Prevention. Serogroup B meningococcal vaccine & outbreaks. Available at: http:\/\/www.cdc.gov\/meningococcal\/outbreaks\/vaccine-serogroupb.html [accessed 15.01.15]."},{"key":"10.1016\/j.vaccine.2015.06.011_bib0640","series-title":"Emergency Preparedness and Response. Notice to Healthcare providers: recognizing and reporting serogroup B meningococcal disease associated with outbreaks at Princeton University and the University of California at Santa Barbara","author":"Centers for Disease Control and Prevention","year":"2013"},{"key":"10.1016\/j.vaccine.2015.06.011_bib0645","series-title":"CDC Newsroom. Meningococcal Disease Update","author":"Centers for Disease Control and Prevention","year":"2014"},{"issue":"22","key":"10.1016\/j.vaccine.2015.06.011_bib0650","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.vaccine.2003.09.022","article-title":"Cost-effectiveness of immunization strategies for the control of serogroup C meningococcal disease","author":"De Wals","year":"2004","journal-title":"Vaccine"},{"issue":"9","key":"10.1016\/j.vaccine.2015.06.011_bib0655","first-page":"596","article-title":"Care of the college student","volume":"88","author":"Unwin","year":"2013","journal-title":"Am J Fam Physician"},{"key":"10.1016\/j.vaccine.2015.06.011_bib0660","series-title":"NFID","article-title":"Bridging from a strong childhood foundation to a healthy adulthood. A report on strategies to increase adolescent immunization rates","author":"The National Foundation for Infectious Diseases","year":"2005"},{"issue":"15","key":"10.1016\/j.vaccine.2015.06.011_bib0665","doi-asserted-by":"crossref","first-page":"E715","DOI":"10.1503\/cmaj.130257","article-title":"Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose","volume":"185","author":"Snape","year":"2013","journal-title":"CMAJ"},{"issue":"9869","key":"10.1016\/j.vaccine.2015.06.011_bib0670","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(12)61961-8","article-title":"Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials","volume":"381","author":"Vesikari","year":"2013","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.vaccine.2015.06.011_bib0675","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/jama.2012.85","article-title":"Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial","volume":"307","author":"Gossger","year":"2012","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.vaccine.2015.06.011_bib0680","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1097\/INF.0b013e3181f59f6d","article-title":"Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial","volume":"29","author":"Snape","year":"2010","journal-title":"Pediatr Infect Dis J"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1500777X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X1500777X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T04:44:55Z","timestamp":1652849095000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X1500777X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":68,"journal-issue":{"issue":"36","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S0264410X1500777X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.06.011","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaccination with a multicomponent meningococcal B vaccine in prevention of disease in adolescents and young adults","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}